Research ExplorerPublicationsHomogeneous EGFR amplification defines a subset of aggressiv...

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.

Standard

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. / Marx, Andreas; Zielinski, Margarete; Kowitz, Charlotte-Marie; Dancau, Ana Maria; Thieltges, Sabrina; Simon, Ronald; Choschzick, Matthias; Yekebas, Emre F.; Kaifi, Jussuf; Mirlacher, Martina; Atanackovic, Djordje; Brümmendorf, Tim; Fiedler, Walter; Bokemeyer, Carsten; Izbicki, Jakob R.; Sauter, Guido.

In: HISTOPATHOLOGY, Vol. 57, No. 3, 3, 2010, p. 418-426.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Marx, A, Zielinski, M, Kowitz, C-M, Dancau, AM, Thieltges, S, Simon, R, Choschzick, M, Yekebas, EF, Kaifi, J, Mirlacher, M, Atanackovic, D, Brümmendorf, T, Fiedler, W, Bokemeyer, C, Izbicki, JR & Sauter, G 2010, 'Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.', HISTOPATHOLOGY, vol. 57, no. 3, 3, pp. 418-426. <http://www.ncbi.nlm.nih.gov/pubmed/20840671?dopt=Citation>

APA

Marx, A., Zielinski, M., Kowitz, C-M., Dancau, A. M., Thieltges, S., Simon, R., Choschzick, M., Yekebas, E. F., Kaifi, J., Mirlacher, M., Atanackovic, D., Brümmendorf, T., Fiedler, W., Bokemeyer, C., Izbicki, J. R., & Sauter, G. (2010). Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. HISTOPATHOLOGY, 57(3), 418-426. [3]. http://www.ncbi.nlm.nih.gov/pubmed/20840671?dopt=Citation

Vancouver

Marx A, Zielinski M, Kowitz C-M, Dancau AM, Thieltges S, Simon R et al. Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. HISTOPATHOLOGY. 2010;57(3):418-426. 3.

Bibtex

@article{50ade706e69444fc828ddba4b3a36d33,
title = "Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.",
abstract = "The epidermal growth factor receptor (EGFR) is a tyrosine kinase (TK) involved in the tumour progression of many cancer types and may serve as an important therapeutic target (erlotinib, cetuximab). Heterogeneity of EGFR amplification and expression could represent a major drawback for anti-EGFR therapy. The aim of this study was performed to determine the potential impact of tumour heterogeneity on anti-EGFR therapy in Barrett's adenocarcinoma (BAC).",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Immunohistochemistry, Lymph Nodes pathology, Prognosis, Adenocarcinoma pathology, Esophageal Neoplasms pathology, Barrett Esophagus metabolism, Gene Amplification, In Situ Hybridization, Fluorescence, Receptor, Epidermal Growth Factor genetics, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Immunohistochemistry, Lymph Nodes pathology, Prognosis, Adenocarcinoma pathology, Esophageal Neoplasms pathology, Barrett Esophagus metabolism, Gene Amplification, In Situ Hybridization, Fluorescence, Receptor, Epidermal Growth Factor genetics",
author = "Andreas Marx and Margarete Zielinski and Charlotte-Marie Kowitz and Dancau, {Ana Maria} and Sabrina Thieltges and Ronald Simon and Matthias Choschzick and Yekebas, {Emre F.} and Jussuf Kaifi and Martina Mirlacher and Djordje Atanackovic and Tim Br{\"u}mmendorf and Walter Fiedler and Carsten Bokemeyer and Izbicki, {Jakob R.} and Guido Sauter",
year = "2010",
language = "Deutsch",
volume = "57",
pages = "418--426",
journal = "HISTOPATHOLOGY",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.

AU - Marx, Andreas

AU - Zielinski, Margarete

AU - Kowitz, Charlotte-Marie

AU - Dancau, Ana Maria

AU - Thieltges, Sabrina

AU - Simon, Ronald

AU - Choschzick, Matthias

AU - Yekebas, Emre F.

AU - Kaifi, Jussuf

AU - Mirlacher, Martina

AU - Atanackovic, Djordje

AU - Brümmendorf, Tim

AU - Fiedler, Walter

AU - Bokemeyer, Carsten

AU - Izbicki, Jakob R.

AU - Sauter, Guido

PY - 2010

Y1 - 2010

N2 - The epidermal growth factor receptor (EGFR) is a tyrosine kinase (TK) involved in the tumour progression of many cancer types and may serve as an important therapeutic target (erlotinib, cetuximab). Heterogeneity of EGFR amplification and expression could represent a major drawback for anti-EGFR therapy. The aim of this study was performed to determine the potential impact of tumour heterogeneity on anti-EGFR therapy in Barrett's adenocarcinoma (BAC).

AB - The epidermal growth factor receptor (EGFR) is a tyrosine kinase (TK) involved in the tumour progression of many cancer types and may serve as an important therapeutic target (erlotinib, cetuximab). Heterogeneity of EGFR amplification and expression could represent a major drawback for anti-EGFR therapy. The aim of this study was performed to determine the potential impact of tumour heterogeneity on anti-EGFR therapy in Barrett's adenocarcinoma (BAC).

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Immunohistochemistry

KW - Lymph Nodes pathology

KW - Prognosis

KW - Adenocarcinoma pathology

KW - Esophageal Neoplasms pathology

KW - Barrett Esophagus metabolism

KW - Gene Amplification

KW - In Situ Hybridization, Fluorescence

KW - Receptor, Epidermal Growth Factor genetics

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Immunohistochemistry

KW - Lymph Nodes pathology

KW - Prognosis

KW - Adenocarcinoma pathology

KW - Esophageal Neoplasms pathology

KW - Barrett Esophagus metabolism

KW - Gene Amplification

KW - In Situ Hybridization, Fluorescence

KW - Receptor, Epidermal Growth Factor genetics

M3 - SCORING: Zeitschriftenaufsatz

VL - 57

SP - 418

EP - 426

JO - HISTOPATHOLOGY

JF - HISTOPATHOLOGY

SN - 0309-0167

IS - 3

M1 - 3

ER -